Maria Reuter, NP
Acute Care · New York, NYNPI 1912323387
Payments from drug & device makers
Across 39 payments — averaging $77.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Akcea Therapeutics, Inc.$620
- Pfizer$100
- Novartis$82
- Novo Nordisk$70
- Irhythm Technologies, Inc.$21
- plus $37 from 2 others
What the payments were for
- Consulting fees$2,18773%
- Food & beverage$82727%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 27 | $2,084 |
| Akcea Therapeutics, Inc. | 1 | $620 |
| Pfizer | 4 | $100 |
| Novartis | 3 | $82 |
| Novo Nordisk | 1 | $70 |
| Irhythm Technologies, Inc. | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $17 |
How this compares
$3,014 in reported general payments places this provider in the 90th percentile of 980 acute care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 179 | $1,417,388 |
| EliquisApixaban | 82 | $80,862 |
| Disopyramide Phosphate | 31 | $9,716 |
| Clonidine | 44 | $5,366 |
| Metoprolol Succinate | 155 | $2,858 |
| Verapamil ErVerapamil Hcl | 51 | $1,838 |
| Pyridostigmine Bromide | 13 | $1,460 |
| Bisoprolol Fumarate | 47 | $1,203 |
| Ezetimibe | 16 | $1,009 |
| Eplerenone | 11 | $871 |
| Telmisartan | 13 | $687 |
| Atorvastatin Calcium | 62 | $564 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 62 | $472 |
| Rosuvastatin Calcium | 32 | $420 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 11 | $397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $2,084 | $1,417,388179 claims |
| PfizerEliquis | $100 | $80,86282 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 980 acute care providers in New York.
Other acute care in New York
- Daniel VerinaNew York$464K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Julie Anne RoldanNew York$10K
- Lauren Dela CruzNew York$9K
- Kristen DonchezNew York$8K
- Tracy Valerie BertizNew York$7K
- Jennifer UllmanNew York$7K
- Sara-Jane DakroubNew York$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.